Abstract | OBJECTIVES: METHODS: Sixteen postmenopausal women (PMW) (mean age 58+/-9 years) with more than two risk factors for coronary artery disease, were randomized to receive either oral estradiol (2 mg) for 28 days or oral estradiol (2 mg) for 14 days and oral estradiol (2 mg) and dydrogesterone (10 mg) for 14 days, in a double-blind, placebo-controlled, single cross-over study. Patients were crossed-over the complementary treatment 7 days after completing the first treatment. The study of forearm blood flow and the measurement of plasma endothelin-1 levels was carried out before and after each treatment. RESULTS: CONCLUSIONS:
|
Authors | Marco Gambacciani, Patrizia Monteleone, Cristiana Vitale, Antonello Silvestri, Massimo Fini, Andrea R Genazzani, Giuseppe M C Rosano |
Journal | Maturitas
(Maturitas)
Vol. 43
Issue 2
Pg. 117-23
(Oct 25 2002)
ISSN: 0378-5122 [Print] Ireland |
PMID | 12385860
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Endothelin-1
- Progesterone Congeners
- Estradiol
- Dydrogesterone
|
Topics |
- Cross-Over Studies
- Double-Blind Method
- Dydrogesterone
(pharmacology)
- Endothelin-1
(blood)
- Endothelium, Vascular
(drug effects)
- Estradiol
(pharmacology)
- Female
- Humans
- Middle Aged
- Premenopause
- Progesterone Congeners
(pharmacology)
- Vasodilation
(drug effects)
|